Hypertonic Saline for MAC
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorOregon Health and Science University
About this trial
The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.
Eligibility criteria
Qualifiers
At least 2 positive MAC sputum cultures in the last 12 months with at least one AFB positive sputum obtained within 12 weeks prior to randomization
Meet American Thoracic Society (ATS)/ Infectious Disease Society of America (IDSA) 2007 pulmonary clinical disease criteria[1]
Age 18 and older
Diagnosis of Bronchiectasis and/or bronchiectatic findings evident on chest CT report
Disqualifiers
Any patient who is unwilling or unable to provide consent or to comply with this protocol
Cavitary NTM disease
Patients who are currently taking or within the prior 6 months received any of the following: bedaquiline, or any component of ATS/IDSA multi-drug recommended therapy (macrolide, ethambutol, rifampin) for MAC treatment
Diagnosis of HIV
Trial design
Treatments tested in this trial
- Hypertonic saline
- Azithromycin
- Ethambutol
- Rifampin
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Oregon Health and Science University
Lead sponsor
NTM Info & Research, Inc.
Collaborator
University Health Network, Toronto
Collaborator
New York University
Collaborator
Source ClinicalTrials.gov